Provided by Tiger Fintech (Singapore) Pte. Ltd.

HUTCHMED

24.200
+0.4401.85%
Volume:7.28M
Turnover:175.40M
Market Cap:21.10B
PE:70.60
High:24.400
Open:23.800
Low:23.720
Close:23.760
52wk High:30.750
52wk Low:18.360
Shares:872.00M
HK Float Shares:872.00M
Volume Ratio:1.55
T/O Rate:0.83%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.343
ROE:46.90%
ROA:-0.81%
PB:2.21
PE(LYR):70.60
PS:4.51

Loading ...

HUTCHMED (00013) Narrows YTD Gain to 5%: When Will the "Bull Market Misser" Rebound?

Stock News
·
Nov 12

Orient Securities Maintains "Buy" Rating on HUTCHMED (00013), Highlights Innovative ATTC Platform

Stock News
·
Nov 10

Orient Securities: First Commercial Insurance Drug List Introduced, Policy Support for Innovative Drugs Becomes Clearer

Stock News
·
Nov 07

CICC Maintains Outperform Rating on HUTCHMED (00013) with Target Price of HK$30

Stock News
·
Nov 07

HUTCHMED Completes Enrollment for Global Phase 3 Study of Lung Cancer Combination Therapy

MT Newswires Live
·
Nov 05

HUTCHMED (00013) Completes Patient Enrollment for Global Phase III SAFFRON Study Evaluating ORPATHYS® (Savolitinib) and TAGRISSO® (Osimertinib) Combination Therapy in MET-Overexpressed/Amplified NSCLC Post-TAGRISSO® Progression

Stock News
·
Nov 05

HUTCHMED Announces Enrollment Completed of Saffron Global Phase Iii Trial of Orpathys® and Tagrisso® Combination for Certain Lung Cancer Patients With Met Overexpression and/or Amplification After Progression on Tagrisso®

THOMSON REUTERS
·
Nov 05

HUTCHMED Announces Enrollment Completed of SAFFRON Global Phase III Trial of ORPATHYS® and TAGRISSO® Combination for Certain Lung Cancer Patients with MET Overexpression and/or Amplification After Progression on TAGRISSO®

GlobeNewswire
·
Nov 05

HUTCHMED (00013.HK) Rises Over 3%

Deep News
·
Nov 04

HUTCHMED (China) Limited (00013) Releases October 2025 Monthly Return with Unchanged Issued Shares

Bulletin Express
·
Nov 03

HUTCHMED (00013) Holds Investor Meeting to Share Latest R&D Progress and Pipeline Updates

Stock News
·
Nov 03

HUTCHMED Unveils Promising ATTC Platform and Advances Lead Cancer Candidate HMPL-A251

Reuters
·
Nov 03

HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event

GlobeNewswire
·
Nov 03

HUTCHMED (China) Limited (13) Highlights Preclinical HMPL-A251 Data at International Oncology Conference

Bulletin Express
·
Oct 23

HUTCHMED (00013) Unveils HMPL-A251 Data at AACR-NCI-EORTC Conference

Stock News
·
Oct 23

HUTCHMED Highlights HMPL-A251 Data Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

GlobeNewswire
·
Oct 23

HUTCHMED (SEHK:13) Announces Vesting of LTIP Awards

Bulletin Express
·
Oct 21

HUTCHMED China Ltd files list of directors to HKEX

Reuters
·
Oct 15

HUTCHMED (00013): Professor Chen Shaowen Appointed as Independent Non-Executive Director and Technical Committee Member

Stock News
·
Oct 14

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

GlobeNewswire
·
Oct 14